← Back to Search

Anti-tumor antibiotic

L-DOS47 + Doxorubicin for Pancreatic Cancer

Phase 1 & 2
Recruiting
Led By Erkut Borazanci, MD
Research Sponsored by Helix BioPharma Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
One or more metastatic tumors measurable on computed tomography (CT) scan per RECIST version 1.1 and screening FDG-PET scan with maximum standardized uptake value (SUV max) ≥ 5.5 for at least one lesion consistent with pancreatic cancer
Acceptable renal function as defined by creatinine ≤1.5x institutional upper limits of normal, or calculated creatinine clearance ≥ 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal
Must not have
Patients with any evidence of uncontrolled brain metastases or carcinomatosis meningitis
Active, uncontrolled bacterial, viral, or fungal infections requiring systematic therapy
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from screening to end of cycle 2, where each treatment cycle is 28 days.
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new drug, L-DOS47, combined with an existing chemotherapy drug, doxorubicin, in patients with advanced pancreatic cancer who have already received treatment. The goal is to find a safe dose and see if this combination can effectively fight the cancer. L-DOS47 helps the immune system attack cancer cells, while doxorubicin kills them directly.

Who is the study for?
Adults with advanced pancreatic cancer who've had prior treatment can join. They need normal kidney, liver, and blood function, no serious heart issues or infections, and a life expectancy of at least 3 months. Participants must not be pregnant or nursing and agree to use contraception.
What is being tested?
The trial tests L-DOS47 combined with doxorubicin on patients with advanced pancreatic cancer to check safety, tolerability, and initial effectiveness against tumors measurable by scans.
What are the potential side effects?
Potential side effects may include reactions related to the immune system due to L-DOS47 and heart problems, nausea, hair loss from Doxorubicin. Specific side effects will be monitored closely.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have at least one tumor from pancreatic cancer that shows up on scans and is active.
Select...
My kidney function is within the required range.
Select...
I am able to care for myself but may not be able to do active work.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I do not have uncontrolled brain cancer spread or meningitis.
Select...
I do not have any ongoing serious infections needing treatment.
Select...
I have severe heart issues, recent heart attack, or unstable heart rhythm.
Select...
I have been diagnosed with HIV, hepatitis B, or hepatitis C.
Select...
My heart's electrical activity tests show a QT interval longer than 480 milliseconds.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from screening to end of cycle 2, where each treatment cycle is 28 days.
This trial's timeline: 3 weeks for screening, Varies for treatment, and from screening to end of cycle 2, where each treatment cycle is 28 days. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Adverse events (as per CTCAE v. 5.0)
Number of complete plus partial responders as per RECIST version 1.1
Secondary study objectives
Carbohydrate antigen (CA) 19-9 biomarker level
Body Weight Changes
Proportion of patients expressing anti-L-DOS47 antibodies

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: L-DOS47 + doxorubicinExperimental Treatment2 Interventions
Patients will be recruited into escalating dosing cohorts of 3, 6 and 9 µg/kg of L-DOS47, with a minimum of 3 and a maximum of 6 patients per cohort. A fixed dose of intravenous doxorubicin \[20 mg/m2/week\] will be administered in combination with L-DOS47 across all cohorts.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
L-DOS47
2012
Completed Phase 2
~80
Doxorubicin
2012
Completed Phase 3
~8030

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
L-DOS47 increases the pH within the tumor microenvironment, enhancing the efficacy of chemotherapeutic agents like doxorubicin. Doxorubicin works by intercalating into DNA, inhibiting cancer cell replication. This combination is significant for pancreatic cancer patients as it targets cancer cells more effectively, potentially improving treatment outcomes and allowing for more personalized treatment plans.

Find a Location

Who is running the clinical trial?

TheradexIndustry Sponsor
33 Previous Clinical Trials
1,549 Total Patients Enrolled
Helix BioPharma CorporationLead Sponsor
3 Previous Clinical Trials
99 Total Patients Enrolled
Erkut Borazanci, MDPrincipal InvestigatorScottsdale Healthcare Hospitals DBA HonorHealth
7 Previous Clinical Trials
383 Total Patients Enrolled
~3 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top